

IMARX THERAPEUTICS INC  
Form 8-K  
June 19, 2009

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 15, 2009

IMARX THERAPEUTICS, INC.  
(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other Jurisdiction of Incorporation)	<b>001-33043</b> (Commission File Number)	<b>86-0974730</b> (IRS Employer Identification No.)
--	--	--

<b>12277 134th NE, Suite 202</b> <b>Redmond, WA</b> (Address of Principal Executive Offices)	<b>98052</b> (Zip Code)
--	----------------------------

Registrant's telephone number, including area code: **(425) 821-5501**

(Former name or former address if changed since last report.)  
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.01 Entry Into a Material Definitive Agreement.**

On June 15, 2009, ImaRx Therapeutics, Inc., ( ImaRx ) and Microbix Biosystems Inc. ( Microbix ) entered into the First Amendment to the Asset Purchase Agreement (the Amendment ), which amended the Asset Purchase Agreement (the Original Agreement ) dated September 22, 2008 between each of them.

The Amendment confirms that the sum of Monthly Chargebacks will not be less than \$500,000, that Microbix shall continue to be responsible for the payment of Monthly Chargebacks up to a total amount of \$500,000 and that anything in the Original Agreement to the contrary notwithstanding Microbix has no outstanding payment or other obligations to ImaRx pursuant to Section 2.3(b) of the Original Agreement and will not in the future have any such obligations to ImaRx.

The amendment further removed Microbix's obligation to provide a detailed report on a monthly basis containing a description of the payments made by Microbix under Section 2.3(b) of the Original Agreement and that Microbix will now provide such a detailed report when the sum of such payments equals or approaches \$500,000.

Finally, the Amendment provides that Microbix shall not be obligated to pay the \$2.5 million bonus due under the Original Agreement on release by the FDA of certain lots of urokinase to ImaRx. Instead, Microbix shall pay to ImaRx a sum of \$200,000 within 90 calendar days of the date of receipt by Microbix of written authorization from the FDA for the release of the urokinase lots should such authorization be received on or before September 1, 2010. A copy of the Amendment is attached hereto as Exhibit 10.1 and is incorporated herein by reference

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

**Exhibit**

<b>No.</b>	<b>Description</b>
10.1	First Amendment to the Asset Purchase Agreement entered into as of June 15, 2009 by and between ImaRx Therapeutics, Inc. and Microbix Biosystems Inc.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 19, 2009

**IMARX THERAPEUTICS, INC.**

By: /s/ Bradford A. Zakes

Bradford A. Zakes,  
President and Chief Executive Officer

**EXHIBIT INDEX**

**Exhibit**

**No.**

10.1

**Description**

First Amendment to the Asset Purchase Agreement entered into as of June 15, 2009 by and between ImaRx Therapeutics, Inc. and Microbix Biosystems Inc.